Overview of comments published [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2010-02-10 19:33 (5965 d 23:30 ago) – Posting: # 4746
Views: 27,661

Dear all,

the “Overview of Comments Received on Draft Guideline on the Investigation of Bioequivalence” (EMA/CHMP/EWP/26817/2010) was published today.
As expected the document is quite heavy (248 pages).
Enjoy, but take your time!

An interesting one (page 157) for people following the MR-guideline (Whenever multiple dose studies are performed it should be demonstrated that steady state has been reached):

Achievement of steady state can be evaluated by collecting pre-dose samples on the day before the PK assessment day and on the PK assessment day. A specific statistical method to assure that steady state has been reached is not considered necessary in bioequivalence studies. Descriptive data is sufficient.

No need for a statistical test (at least for EMA). I have to revise my previous recommendations (like in this post).

A comment on replicate designs (page 185) As there is still some controversy around replicate design studies and the statistical analysis, it would be very helpful if more detailed recommendations could be given here. What statistical analyses to be used? How to evaluate a replicate design in an average BE approach?
Was answered by

It is out of the scope of the guideline to give details on how to analyse the data of a replicate design, since it is standard statistical analysis.


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
127 visitors (0 registered, 127 guests [including 10 identified bots]).
Forum time: 20:04 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5